Vericiguat
Intervention1 paper3 findingsPubChem 54674461ChEBI 142432
C · W · M · H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
Labs are independent when their papers share no last author and no institution.
Against: findings that point the other way from most findings on the same outcome.
No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.
Company ties: findings with an author at a company, or from a paper that declares the maker’s interest.
Funder: Bayer3 of 3 findings with company ties
- Human trial1
Outcomes
2Lifespan
upin humans1
1 study
Lifespan
upin humans1
Vericiguat improves lifespan in humans.
Human trialheart failure with reduced ejection fraction1 and 2 years
Mortality benefit and lifetime survival gains with vericiguat in HFrEF: Bayesian and actuarial analyses of the VICTOR trial · European journal of heart failure · 16 Sep 2026
Vericiguat extends lifespan in humans (∼1.6 to 1.9 years).
Human trialheart failure with reduced ejection fraction
Mortality benefit and lifetime survival gains with vericiguat in HFrEF: Bayesian and actuarial analyses of the VICTOR trial · European journal of heart failure · 16 Sep 2026
Mortality
downin humans1−98% posterior probability of any benefit
1 study
Mortality
downin humans1−98% posterior probability of any benefit
Vericiguat decreases mortality in humans (98.4% posterior probability of any benefit).
Human trialheart failure with reduced ejection fraction
Mortality benefit and lifetime survival gains with vericiguat in HFrEF: Bayesian and actuarial analyses of the VICTOR trial · European journal of heart failure · 16 Sep 2026